Biocon Biologics gets US market entry date for Bmab 1200, a proposed biosimilar to Stelara EP News Bureau Mar 1, 2024 Stelara (Ustekinumab) has been approved for the treatment of psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis and…
